Lukewarm response to cold war on international pricing index

PhRMA and BIO have gone to war against the Trump administration’s proposal to reference some Medicare Part B drug prices to a basket of prices paid in other countries, but they haven’t found many allies in Congress.

Lobbying campaigns and advertising by the trade associations, the U.S. Chamber of Commerce and several conservative groups have not led a single Republican Senator to publicly condemn the international pricing index (IPI) proposal. ...